S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in

Agile Therapeutics (NASDAQ:AGRX) Cut to "Sell" at Zacks Investment Research

Last updated on Wednesday, January 13, 2021 | 2021 MarketBeat

Agile Therapeutics (NASDAQ:AGRX) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. "

A number of other analysts also recently weighed in on the company. William Blair restated a "buy" rating on shares of Agile Therapeutics in a report on Friday, September 25th. Royal Bank of Canada restated a "buy" rating and issued a $8.00 price objective on shares of Agile Therapeutics in a report on Monday, November 16th. BidaskClub downgraded Agile Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, January 7th. Oppenheimer reiterated a "buy" rating and set a $10.00 price target on shares of Agile Therapeutics in a report on Tuesday, December 8th. Finally, HC Wainwright increased their price target on Agile Therapeutics from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Tuesday, December 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Agile Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $7.67.

Shares of AGRX traded down $0.04 during trading hours on Wednesday, reaching $2.84. The stock had a trading volume of 20,691 shares, compared to its average volume of 912,773. Agile Therapeutics has a 12 month low of $1.35 and a 12 month high of $4.77. The stock has a market capitalization of $248.32 million, a PE ratio of -5.68 and a beta of 1.32. The company has a debt-to-equity ratio of 0.24, a quick ratio of 10.18 and a current ratio of 10.18. The company's 50-day moving average is $2.88 and its two-hundred day moving average is $2.90.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Tuesday, November 17th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.18). Equities analysts anticipate that Agile Therapeutics will post -0.64 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in AGRX. The Manufacturers Life Insurance Company boosted its position in shares of Agile Therapeutics by 1,924.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 869,920 shares of the specialty pharmaceutical company's stock worth $2,645,000 after purchasing an additional 826,947 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of Agile Therapeutics in the 2nd quarter worth $888,000. GSA Capital Partners LLP acquired a new stake in shares of Agile Therapeutics in the 3rd quarter worth $693,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Agile Therapeutics in the 2nd quarter worth $494,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Agile Therapeutics by 276.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 210,048 shares of the specialty pharmaceutical company's stock worth $584,000 after acquiring an additional 154,193 shares during the period. 44.44% of the stock is currently owned by institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading: What sectors are represented in the FTSE 100 index?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Food Stocks That Are Leading Through Innovation

It might be easy to dismiss food stocks with so many restaurants still struggling to recover from the global pandemic. But food stocks are a broad category that includes not only the way food is consumed but the way it’s made. In 2020, sustainability and a focus on climate change continue to be important trends in this sector.

Another trend to look at is the ability of companies to deliver food to consumers. It’s not surprising that some of the biggest winners in the pandemic are the restaurants that already had a strong digital presence. Consumers' ability to have a contactless experience from start to finish has been a catalyst for some stocks.

Not surprisingly, those are also the trends that create an opportunity for investors looking to dabble in food stocks. As you look to resetting your portfolio for 2021, it may be time to take a bite out of some of these stocks.

With that in mind, we’ve put together this special presentation that identifies seven food stocks that you should consider adding to your portfolio. In addition to gaining exposure to this sector, some of these stocks present the opportunity for industry-beating gains.

View the "7 Food Stocks That Are Leading Through Innovation".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.